Last reviewed · How we verify

NVN1000 8% Gel

Novan, Inc. · Phase 2 active Small molecule

NVN1000 8% Gel is a Small molecule drug developed by Novan, Inc.. It is currently in Phase 2 development. Also known as: SB206.

At a glance

Generic nameNVN1000 8% Gel
Also known asSB206
SponsorNovan, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NVN1000 8% Gel

What is NVN1000 8% Gel?

NVN1000 8% Gel is a Small molecule drug developed by Novan, Inc..

Who makes NVN1000 8% Gel?

NVN1000 8% Gel is developed by Novan, Inc. (see full Novan, Inc. pipeline at /company/novan-inc).

Is NVN1000 8% Gel also known as anything else?

NVN1000 8% Gel is also known as SB206.

What development phase is NVN1000 8% Gel in?

NVN1000 8% Gel is in Phase 2.

Related